Switching from Sprycel (dasatinib) to Scemblix (asciminib) is something others in the leukemia community have navigated too. Scemblix is a newer TKI that was FDA-approved in 2024 and works a bit differently than older TKIs, which is one reason doctors may switch patients to it.
Here are some common side effects that showed Show Full Answer
Switching from Sprycel (dasatinib) to Scemblix (asciminib) is something others in the leukemia community have navigated too. Scemblix is a newer TKI that was FDA-approved in 2024 and works a bit differently than older TKIs, which is one reason doctors may switch patients to it.
Here are some common side effects that showed up in clinical trials for Scemblix:
- Low platelet count (thrombocytopenia)
- Low white blood cell count (neutropenia)
- Diarrhea
- Fatigue
- Muscle pain
The good news is that for many people, side effects tend to become less noticeable over time. One important thing to know about taking Scemblix — it should not be taken with food. This is different from some other TKIs, so it's worth building that into a daily routine to make sure it's taken correctly.
Missing doses can affect how well the treatment works, so consistency really matters. If side effects make it hard to stay on track, it's worth being open with the care team — they can often suggest ways to manage them.
Many MyLeukemiaTeam members share their experiences with medication switches, so connecting with others who've made a similar transition can be really reassuring.
August 30
Join
Your Privacy Choices
